Search | Clinical Trials Finder

Conditions: Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
Interventions: Cardio-Oncology Referral, Notification to PCP/General Cardiologist; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 45 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Androgenetic Alopecia
Interventions: KX0826, Placebo; Drug · Other
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: AZD9750, AZD5305; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Duarte, California • San Francisco, California • Tampa, Florida + 5 more

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Docetaxel, Imatinib Mesylate; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: New York, New York

Conditions: Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions: enzalutamide, CRLX101; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: GT0918; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Towson, Maryland • Omaha, Nebraska • Las Vegas, Nevada + 3 more

Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions: NX-1607, Paclitaxel; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan; Drug · Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congenital Adrenal Hyperplasia (CAH)
Interventions: Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Enzalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 5
States / cities: Boston, Massachusetts • Weymouth, Massachusetts • Seattle, Washington

Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Androgen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, PTEN Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Alpelisib, Enzalutamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Prostate Carcinoma
Interventions: androgen receptor signaling inhibitors; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ONCT-534; Drug
Lead sponsor: Oncternal Therapeutics, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • Omaha, Nebraska + 6 more

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Brachytherapy; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941; Drug · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 13
States / cities: San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: Prostate Cancer
Interventions: ADT, ARSI, No ADT/ARSI -decline; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Interventions: AMO959, AAA617, Enzalutamide, Abiraterone; Drug · Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • El Paso, Texas • Murray, Utah

Conditions: Prostatic Cancer, Castration-Resistant
Interventions: JSB462, AAA617; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Duarte, California • Santa Monica, California • Denver, Colorado + 7 more

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions: KTX-2001, KTX-2001 + Darolutamide (NUBEQA®); Drug
Lead sponsor: K36 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Metastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Prostate Carcinoma Metastatic to the Bone
Interventions: Robotic Assisted Radical Prostatectomy, Conventional open retropubic radical prostectomy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide); Procedure · Other · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Duarte, California • Orange, California • New Brunswick, New Jersey

Search by objective public record fields.

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

A Study of NX-1607 in Adults With Advanced Malignancies

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Physical Function During ARSI Treatment

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer